Towards improved HIV-microbicide activity through the co-encapsulation of NRTI drugs in biocompatible metal organic framework nanocarriers. Issue 43 (25th October 2017)

• Record Type: Journal Article
• Authors: Marcos-Almaraz, M. T.; Gref, R.; Agostoni, V.; Kreuz, C.; Clayette, P.; Serre, C.; Couvreur, P.; Horcajada, P.
• Is Part Of: Journal of materials chemistry. Volume 5:Issue 43(2017)
• Page Start: 8563
• Page End: 8569
• Publication Date: 2017-10-25
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c7tb01933e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Stable and active nano-formulations of the biocompatible MOF MIL-100(Fe) coencapsulating two anti-HIV drugs are proposed as efficient HIV microbicides. Abstract : The efficacy of the routinely used anti-HIV (Human Immunodeficiency Virus) therapy based on nucleoside reverse transcriptase inhibitors (NRTIs) is limited by the poor cellular uptake of the active triphosphorylated metabolites and the low efficiency of intracellular phosphorylation of their prodrugs. Nanoparticles of iron(iii ) polycarboxylate Metal–Organic Frameworks (nanoMOFs) are promising drug nanocarriers. In this study, two active triphosphorylated NRTIs, azidothymidine triphosphate (AZT-Tp) and lamivudine triphosphate (3TC-Tp), were successfully co-encapsulated into the biocompatible mesoporous iron(iii ) trimesate MIL-100(Fe) nanoMOF in order to improve anti-HIV therapies. The drug loaded nanoMOFs could be stored for up to 2-months and reconstituted after freeze drying, retaining similar physicochemical properties. Their antiretroviral activity was evidenced in vitro on monocyte-derived macrophages experimentally infected with HIV, making these co-encapsulated nanosystems excellent HIV-microbicide candidates.